- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04526587
Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. Delineate clinical features of disease progression and responses to subsequent therapy following progression on ciclib-based therapy.
II. Define pharmacogenomics relationships that could provide a more precise approach to drug dosing.
III. Interrogate biomarkers related to response and acquired resistance in standard clinical practice.
IV. Develop patient-derived models from resistant disease to functionally assess the mechanisms occurring with resistance.
V. Elucidate the socio-demographic features related to the use of ciclibs clinically in the Roswell Park catchment area.
OUTLINE:
Patients electronic medical records are reviewed to capture clinical information, and patients undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples for diagnosis/treatment decision, biomarker assessments, and description of mechanisms of resistance/response related to ciclib-therapy.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
Contact:
- Agnieszka K. Witkiewicz
- Phone Number: 716-845-1224
- Email: Agnieszka.Witkiewicz@roswellpark.org
-
Principal Investigator:
- Agnieszka K. Witkiewicz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
All adult patients with ER+/HER2- metastatic breast cancer or HR+/HER2-node positive, high risk early breast cancer who are being or have been treated with ciclib-based therapies are eligible for inclusion in this study
- This includes patients receiving standard of care therapy for ER+/HER2- metastatic breast cancer, as well as those who would be eligible to participate in a non-interventional study while on a clinical study open at Roswell Park or St. Vincent's Hospital
- Screening will occur in breast oncology clinic, by review of patient medical records for the pending, ongoing, or past treatment with ciclib-based therapy
- Participant must understand the prospective nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form
Exclusion Criteria:
- Pregnant of nursing female subjects
- Unwilling or unable to follow protocol requirements
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Basic science (medical chart review, biospecimen collection)
Patients electronic medical records are reviewed to capture clinical information, and patients undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples for diagnosis/treatment decision, biomarker assessments, and description of mechanisms of resistance/response related to ciclib-therapy.
|
Correlative studies
Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
Other Names:
Patient's electronic health records are reviewed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collection of clinical characteristics
Time Frame: Up to 5 years
|
Will be summarized by ciclib treatment regimen using the appropriate descriptive statistics.
Differences will be evaluated using the Kruskal-Wallis and Chi-square tests, as appropriate.
|
Up to 5 years
|
Overall survival on ciclib
Time Frame: Up to 15 years
|
Will be summarized by treatment regimen using standard Kaplan-Meier methods, with comparisons made using the log rank test.
Cox regression models with time-dependent variables may be considered to account for changing treatment regimens and other patient characteristics.
|
Up to 15 years
|
Progression-free survival on ciclib
Time Frame: Up to 15 years
|
Will be summarized by treatment regimen using standard Kaplan-Meier methods, with comparisons made using the log rank test.
Cox regression models may be considered to adjust for prior therapies and other patient characteristics.
|
Up to 15 years
|
Progression-free survival on subsequent therapies
Time Frame: Up to 15 years
|
Will be summarized by treatment regimen using standard Kaplan-Meier methods, with comparisons made using the logrank test.
Cox regression models may be considered to adjust for prior therapies and other patient characteristics.
|
Up to 15 years
|
Site of the metastatic disease and time to progression
Time Frame: Up to 5 years
|
Development of and location of metastatic disease will be summarized using the appropriate descriptive statistics.
|
Up to 5 years
|
Incidence of treatment related toxicities
Time Frame: Up to 5 years
|
Will be summarized by ciclib treatment regimen using frequencies and relative frequencies.
Comparisons may be made using Fisher's exact test.
Associations between toxicity rates and patient demographic/clinical characteristics may be evaluated using logistic regression models.
|
Up to 5 years
|
Genetic variance of genes associated with ciclib metabolism
Time Frame: Up to 5 years
|
Will be summarized in the overall sample and by treatment regimen using the appropriate descriptive statistics and graphical summaries.
The association between these genetic features and toxicity and survival outcomes will be evaluated using stratified Cox regression models, where genotype will be the stratification factor.
Additional models may be considered to account for other demographic or clinical characteristics.
Hazard ratios with 95% confidence intervals will be obtained from model estimates.
|
Up to 5 years
|
Quantitative biomarker expressions
Time Frame: Up to 5 years
|
Will be summarized in the overall sample and by treatment regimen using the appropriate descriptive statistics and graphical summaries.
The association between baseline biomarkers and survival outcomes will be evaluated using stratified Cox regression models, where treatment regimen will be the stratification factor.
Additional models may be considered to account for other demographic or clinical characteristics.
Hazard ratios with 95% confidence intervals will be obtained from model estimates.
|
Up to 5 years
|
Development of patient-derived models from resistant disease
Time Frame: Up to 5 years
|
Will be evaluated to functionally assess the mechanisms occurring with resistance.
No formal statistical analyses will be performed in regards to the development of organoid and patient-derived xenograft (PDX) models.
|
Up to 5 years
|
Socio-economic features related to the use of ciclibs
Time Frame: Up to 5 years
|
Will be elucidated clinically in the Roswell Park catchment area.
Treatment regimens and sequences may be summarized by patient demographic and socio-economic characteristics using frequencies and relative frequencies.
Associations may be evaluated using Chi-square tests.
|
Up to 5 years
|
Clinical course of CDK4/6 inhibitor treated patients in the "real-world" setting
Time Frame: Up to 5 years
|
Will involve interrogating ciclib treatment patterns, treatment choices post progression, toxicities, clinical responses following progression, and ultimately differences in overall survival.
|
Up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Examination of biomarkers of response
Time Frame: Up to 5 years
|
Will examine biomarkers of response/resistance and association with long term outcomes relative to pretreatment controls.
|
Up to 5 years
|
Single-nucleotide polymorphisms
Time Frame: Day 8 to day 18 of cycle 1
|
Blood will be collected to interrogate single-nucleotide polymorphisms in CYP3A4 and related genes associated with metabolism of ciclib compounds.
These polymorphisms will be related to dose limiting toxicities and dose interruptions.
Blood samples for pharmacokinetic and pharmacogenomic analysis will be drawn during regular laboratory blood draws.
|
Day 8 to day 18 of cycle 1
|
Circulating cell free DNA (cfDNA)
Time Frame: Up to 5 years
|
Serial peripheral blood samples will be prospectively collected at specified time points and processed for cfDNA and circulating tumor cells (CTC) isolation.
CTCs will be utilized for the development of 3-dimensional (3D) organoid cultures and CTC-derived xenograft models.
|
Up to 5 years
|
Development of functional models (patient-derived models) from individuals with progressive disease
Time Frame: Up to 5 years
|
Will only employ tissues and /or body fluids that are being discarded or do not involve any additional procedures for the patients.
This includes, excess tissue that is not required for diagnosis or pleural effusions or peritoneal ascites.
Cells isolated from the samples will be used for the development of organoid or PDX models.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Agnieszka K Witkiewicz, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I 571719 (Other Identifier: Roswell Park Cancer Institute)
- NCI-2020-05682 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anatomic Stage IV Breast Cancer AJCC v8
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterNovartis; Seagen Inc.RecruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)RecruitingAnatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
Clinical Trials on Diagnostic Laboratory Biomarker Analysis
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Proliferations Associated With Down SyndromeUnited States, Canada, Australia, Puerto Rico
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Light Chain Deposition DiseaseUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Stage 4S NeuroblastomaUnited States